Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2025 · 10-Q
Revenue$89.01M$89.01M+469.8% vs Q1 2024 Net Income$6.08M$6.08MN/M vs Q1 2024 EPS Diluted$0.12$0.12N/M vs Q1 2024 Operating Income$12,127,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived$32,605,000N/M Margins · derivedOperating margin13.6%+422.4 pt vs Q1 2024
Net margin6.8%+412.2 pt vs Q1 2024
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end